Filing Details

Accession Number:
0001209191-23-007907
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-08 19:18:52
Reporting Period:
2023-02-06
Accepted Time:
2023-02-08 19:18:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643653 Eric Benevich 12780 El Camino Real
San Diego CA 92130
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-06 1,280 $105.63 17,879 No 4 S Direct
Common Stock Disposition 2023-02-07 2,030 $102.29 19,705 No 4 S Direct
Common Stock Disposition 2023-02-07 15,360 $102.42 33,501 No 4 S Direct
Common Stock Disposition 2023-02-08 980 $104.12 34,381 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.60 to $107.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.74 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. Sale of 15,360 shares of common stock issued upon vesting of 29,156 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (13,796) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  6. The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.
  7. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.02 to $103.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  9. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.